2019 systematic review places this human trial history in context alongside the broader musculoskeletal preclinical literature
Pro-angiogenic BPC157 associated with VEGFR2 activation and up-regulation
This includes leg cramps, constipation, irregular heartbeats, fluttering in the chest, increased thirst or urination, numbness or tingling, muscle weakness, or limp feeling
Neutral or highly hydrophobic peptides containing a high proportion of polar uncharged amino acids and/or hydrophobic amino acids should be dissolved in a small amount of an organic solvent such as DMSO, DMF, acetic acid, acetonitrile, methanol, propanol, or isopropanol and then diluted with water (or buffer) to the desired concentration
We dont offer it to everyone, and we dont minimize the regulatory landscape around it
Off phase: 2 months pause